Feb 20, 2026 04:01PM
Feb 3, 2026 08:02AM
Feb 3, 2026 08:00AM
Dec 19, 2025 07:45AM
Dec 19, 2025 07:45AM
Dec 4, 2025 08:30AM
Nov 4, 2025 07:00AM Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Jul 31, 2025 07:00AM
May 1, 2025 07:00AM
Apr 30, 2025 07:12PM
Feb 19, 2025 07:00AM
Jan 12, 2025 04:00PM
Nov 6, 2024 07:00AM
Oct 17, 2024 07:01AM Amicus Therapeutics (FOLD) Announces Settlement of Galafold Patent Litigation with Teva (TEVA)
Oct 17, 2024 07:00AM
Aug 8, 2024 07:00AM
May 30, 2024 05:50AM
May 9, 2024 07:00AM
Mar 26, 2024 09:53AM
Feb 28, 2024 07:00AM
Feb 8, 2024 07:00AM Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
Jan 8, 2024 05:24AM
Jan 7, 2024 04:00PM
Nov 8, 2023 07:00AM
Oct 1, 2023 08:30PM
Sep 28, 2023 10:41AM
Sep 28, 2023 10:41AM
Aug 23, 2023 09:19AM WuXi Biologics Reports Solid 2023 Interim Results
Aug 22, 2023 09:17AM
Aug 8, 2023 07:00AM
Jun 27, 2023 07:00AM
May 10, 2023 07:00AM
Mar 1, 2023 07:00AM
Feb 22, 2023 05:00PM
Feb 22, 2023 05:00PM Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Jan 9, 2023 07:17AM
Jan 9, 2023 07:00AM
Nov 7, 2022 07:00AM
Oct 28, 2022 04:01PM
Oct 28, 2022 04:01PM
Aug 4, 2022 07:00AM
May 10, 2022 04:01PM Amicus Therapeutics (FOLD) Announces 90-Days PDUFA Date Extensions for AT-GAA
May 10, 2022 04:01PM
May 9, 2022 09:15AM
May 9, 2022 07:00AM
Apr 19, 2022 07:02AM
Apr 19, 2022 07:00AM
Mar 16, 2022 07:01AM
Mar 16, 2022 07:00AM Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
Feb 24, 2022 07:00AM

322,914 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All